Research programme: monoclonal antibodies - Humabs BioMed

Drug Profile

Research programme: monoclonal antibodies - Humabs BioMed

Alternative Names: RVC 20; RVC 58

Latest Information Update: 24 Aug 2016

Price : $50

At a glance

  • Originator Humabs BioMed
  • Developer Humabs BioMed; Swiss Tropical and Public Health Institute; University of California at Berkeley
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Infections

Highest Development Phases

  • Preclinical Dengue; Ebola virus infections; Hepatitis B; Influenza B virus infections; Metapneumovirus infections; Middle East respiratory syndrome coronavirus; Norovirus infections; Rabies; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Staphylococcal infections; Zika virus infection
  • Research Cancer; Herpes simplex virus infections

Most Recent Events

  • 14 Jul 2016 Preclinical trials in Zika virus infection in Switzerland (Parenteral)
  • 01 Apr 2016 monoclonal antibodies - Humabs BioMed is available for licensing in World as of 11 Apr 2016.
  • 13 Oct 2015 Preclinical trials in Rabies in United Kingdom, France, Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top